- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07631078
kTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery (KULMINATE) Pilot
kTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery
kTMP, kilohertz transcutaneous magnetic perturbations, is a low intensity transcranial magnetic stimulation technique that will be used in this study to promote arm/hand rehabilitation in patients who have been disabled by stroke.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
The goal of this pilot clinical trial is to assess the feasibility and preliminary efficacy of kTMP on upper limb motor recovery in chronic stroke compared to sham. We will conduct a 6-week double-blind, randomized, sham-controlled pilot study to test the beneficial influence of kTMP combined with simple motor tasks on kinematic outcomes such as range of motion of the upper arm, hand and fingers.
After baseline assessments, participants will be randomly allocated to either the kTMP group or the Control group. Participants, experimentalists, and outcome assessors will be blinded to group allocation. kTMP will begin within 1 week following randomization and will be delivered three times a week for 6 weeks. The primary endpoint will be assessed at the end of treatment, with follow-up assessments occurring 1 month, 3 months and 6 months following treatment completion. There is one assessment 4 weeks into the treatment phase to assess if patients continue to improve from 4 to 6 weeks of treatment.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Ludovica Labruna, PhD
- Número de telefone: 5104237125
- E-mail: participate@magnetictides.com
Locais de estudo
-
-
California
-
San Francisco, California, Estados Unidos, 94158
- Recrutamento
- UCSF Mission Bay- Sandler Neurosciences Center
-
Contato:
- Christina Merrick
- Número de telefone: 510-423-7125
- E-mail: participate@magnetictides.com
-
Investigador principal:
- Ludovica Labruna, PhD
-
Investigador principal:
- Richard Ivry, PhD
-
Investigador principal:
- Karunesh Ganguly, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
- Adults aged 18-80 years who have a history of an ischemic or hemorrhagic stroke ≥ 12 m prior to enrollment.
- Fugl-Meyer Assessment: Upper Extremity (FMA UE) score 20-50.
- Ability to communicate, understand, and give appropriate consent. Participants can follow two-step commands.
- Motor evoked potentials in a hand muscle when stimulating ipsilesional cortex with suprathreshold single-pulse TMS (MEP positive).
Exclusion criteria:
- Participants with moderate or severe cognitive impairment (MMSE < 18).
- Participants with sensory deficits FMA-S < 6/12 (with proprioception < 4/8).
- Participants with severe apraxia (TULIA < 5).
- Language impairment or behavioral disorder that interferes with their ability to adhere to the protocol or to provide informed consent.
- Individuals who have a serious uncontrolled medical condition, including but not limited to severe cardiovascular and cardiopulmonary disease.
- Pregnancy or plans to become pregnant during the study period.
- Botulinum toxin injections of the affected upper extremity within 3 months prior to onset of study.
- Severe spasticity of the affected upper limb (Modified Ashworth ≥ 4).
- Absolute contraindications related to non-invasive brain stimulation, including:
9a) History of seizures in the last 12 months while taking anti-epilepsy medication 9b) Presence of any metal implants in the head (excluding the mouth), such as cortical stimulators and DBS, clips, coils, shunts, stents or skull plates, cochlear implants 9c) Permanent eye liner or head tattoos 9d) Implanted electronics such as pacemakers, defibrillators, intrathecal baclofen pumps or vagus nerve stimulator 9e) History of experiencing a serious adverse event during a previous transcranial magnetic stimulation (TMS) session
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Active kTMP
Participants received 8 V/m of active stimulation |
A new non-invasive brain stimulation tool |
|
Comparador Falso: Sham kTMP
Participants receive sham stimulation (0.0 V/m electric field) |
A new non-invasive brain stimulation tool with sham setting selected |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Movement Quality Index (MQI)
Prazo: Enrollment, then weeks 4, 6, 10, 18, 30
|
Kinematic data will be captured using a markerless, three-camera motion tracking system during a standardized reach-to-grasp task, with 30 trials per assessment. The cameras will reconstruct 3D hand, arm, and shoulder motion. The primary outcome is change from baseline in the Movement Quality Index (MQI), compared between kTMP and sham groups. MQI is a composite kinematic score calculated as range of motion (ROM) divided by trial-to-trial variability (T2TV), both derived from the 3D reconstructions: ROM: range, speed, and smoothness of hand/arm motion, including elbow and shoulder joint angles. T2TV: consistency across trials, measured as variance of 3D trajectories around the mean trajectory. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fugl- Meyer Assessment (Upper Extremity) FMA-UE
Prazo: Enrollment, then weeks 4, 6, 10, 18, 30
|
The Fugl-Meyer Assessment (FMA) is a structured evaluation used to measure motor recovery after a stroke, with a total score range of 0-226. Higher scores indicate better motor function, while lower scores reflect greater impairment. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Modified Ashworth Scale (MAS)
Prazo: Enrollment, then weeks 4, 6, 10, 18, 30
|
Test of resistance to passive movement about a joint, scores range from 0 to 5 where 0=no increase in muscle tone and 5=affected part(s) rigid. Hight scores indicate greater muscle tone. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Stroke Impact Scale (SIS)
Prazo: Enrollment, then weeks 4, 6, 10, 18, 30
|
Self reported questionnaire that evaluates disability and health related quality of life after stroke, consisting of 59 items, assessing strength, hand function, ADL/iADL, mobility, communication, emotion, memory and thinking, participation/role function. Each item is rated in a 5 point Likert scale, where 1 equals could not do it at all and 5 equals not difficult at all. Score ranges 0-100. Higher score indicates less disability and high quality of life after stroke. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
EuroQOL (EQ-5D)
Prazo: Enrollment, then weeks 4, 6, 10, 18, 30
|
A health questionnaire that measures 5 dimensions including mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each item is described by 3 levels of problems, where 1=none, 2=mild to moderate, and 3=severe. This provides a simple single index value for health status, where a higher score indicates worse health state. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Motor Activity Log (MAL)
Prazo: Enrollment, then weeks 4, 6, 10, 18, 30
|
Self reported perception of Quality of movement are rated in 30 functional tasks, scored on a 6 point ordinal scale where 0=weaker arm not used at all for that activity and 5=ability to use the weaker arm for that activity is as good as before the stroke(normal). A higher score indicates better quality upper extremity movement. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Wolf Motor Function Test (WMFT)
Prazo: Enrollment, then weeks 4, 6, 10, 18, 30
|
A quantitative measure of upper extremity motor abilitythrough timed and functional tasks will be administered by a trained experimenter. |
Enrollment, then weeks 4, 6, 10, 18, 30
|
|
Stroke Specific QOL (SSQOL)
Prazo: At enrollment, then weeks 4, 6, 10, 18, and 30
|
Questionnaire consisting of 49 items in the 12 domains of mobility, energy, upper extremity function, work and productivity, mood, self-care, social roles, family roles, vision, language, thinking and personality. Each item is assessed on a 5 point Guttman type scale, where 1=total help; couldn't do it at all; strongly agree and 5 =no help needed; no trouble at all; strongly disagree. Higher scores indicate better functioning. |
At enrollment, then weeks 4, 6, 10, 18, and 30
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- Derrame
- Estimulação magnética transcraniana
- AVC Isquêmico
- Estimulação cerebral não invasiva
- Excitabilidade Cortical
- AVC Crônico
- Plasticidade
- Distúrbios Cerebrovasculares
- Distúrbios cerebrais
- Distúrbios do Sistema Nervoso Central
- Derrame cerebral
- Distúrbios cardiovasculares
- kTMP
- quilohertz perturbação magnética transcraniana
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- kTMPstrokePilot
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .